Trending...
- Sterling Heights City Clerk's Office releases new voting precinct map
- African Arts Academy Hosts Modern Ethnic Fashion Show in San Francisco communities
- Growing Up Beckham: Kordell Beckham Makes Runway Debut
What I Wish I Knew a Year Ago About the Aesthetic Market and Where I'm Investing Now
VANCOUVER, British Columbia - Michimich -- In 1978, scientists isolated human insulin produced by genetically modified E. coli, marking the first biopharmaceutical derived from recombinant DNA technology. This radically new methodology for isolating enzymes and active ingredients shook biotechnology to the core, triggering a tsunami of discoveries. Since then, more than 250 therapeutic proteins and monoclonal antibodies have stolen the stage as standard of care.
In the last several years, this momentum carried over to cosmetics, as biotechnology and aesthetic medicines joined forces to isolate anti-aging skin products such as hyaluronic acid, kojic acid, and resveratrol, to name a few. But what new developments stand on the horizon? And to which direction should investors hone their gaze? Two emerging therapies, stem cell exosomes and gene therapy, scintillate brightly on the financial horizon as golden investment opportunities.
The global biotech aesthetic market size valued at USD 63.5 billion in 2021, with the compound annual growth rate (CAGR) projected to increase by 9.6% from 2022 to 2023, according to the aesthetic medicine market size report. Social distancing, sudden cuts in consumers' income levels, and temporary closures of beauty centers balanced the inevitable bottleneck in manufacturing and supply chains. The pandemic, however, saw the workforce shift to remote Zoom calls, forcing many to pay close attention to facial appearance. The market consequently saw a spike in non-invasive aesthetic treatments, with this segment dominating the market in 2021 with shares over 50%. The non-invasive aesthetic treatment market size was valued at USD 52 billion last year with a CAGR of 12.4%.
More on Michimich.com
Currently, 45 market competitors compose the exosome industry, with 19 of them being established companies that have recently joined the race to develop aging-defying exosome technology. Some of these companies include: Galderma S.A., Johnson & Johnson, Allergen, El. En. SpA, Alma Lasers, Cynosure, Lumenis, Solta Medical, Syneron Candela, and Merz Pharma.
Up and coming regenerative biotech company Elevai shows award winning promise with stem cell exosome topical applications as the next generation of targeted anti-aging skin care. Elevai recently won the LaunchPad SBDC People's Choice Award at the 2022 Octane Aesthetics Tech Summit ("ATS") held in Newport Beach, California, for their proprietary stem cell exosome technology and products. The Elevai platform technology illuminates potential applications in regenerative medicine and in office medical skincare treatments.
Another company worth mentioning includes Jeune, a gene-based aesthetic subsidiary of Krystal biotech, that is currently operating the first-in-human Phase 1 clinical trial of an injectable gene therapy to stimulate production of collagen type III and reduce wrinkles. The injections were well tolerated and biopsies at the injection sites showed new collagen generation, an excellent first step to directly address biological changes in the skin associated with intrinsic and extrinsic aging.
More on Michimich.com
Stem cell exosomes and gene therapy technologies will no doubt become the in office standard of care for regenerative and anti-aging technology, stealing the stage much in the same way that insulin radically changed diabetic care.
In the last several years, this momentum carried over to cosmetics, as biotechnology and aesthetic medicines joined forces to isolate anti-aging skin products such as hyaluronic acid, kojic acid, and resveratrol, to name a few. But what new developments stand on the horizon? And to which direction should investors hone their gaze? Two emerging therapies, stem cell exosomes and gene therapy, scintillate brightly on the financial horizon as golden investment opportunities.
The global biotech aesthetic market size valued at USD 63.5 billion in 2021, with the compound annual growth rate (CAGR) projected to increase by 9.6% from 2022 to 2023, according to the aesthetic medicine market size report. Social distancing, sudden cuts in consumers' income levels, and temporary closures of beauty centers balanced the inevitable bottleneck in manufacturing and supply chains. The pandemic, however, saw the workforce shift to remote Zoom calls, forcing many to pay close attention to facial appearance. The market consequently saw a spike in non-invasive aesthetic treatments, with this segment dominating the market in 2021 with shares over 50%. The non-invasive aesthetic treatment market size was valued at USD 52 billion last year with a CAGR of 12.4%.
More on Michimich.com
- Sterling Heights Fire Department becomes first in Michigan to utilize Remote Methane Leak Detector
- Implement The Exploration Of Charity In The Virtual World Concept Till The Very End
- IONETIX AND ATONCO SIGN A PARTNERSHIP AGREEMENT TO FIGHT BLADDER CANCER
- Global Changemakers Celebrate Black Women In Film At Cannes Film Festival In Response To Gross Underrepresentation In Competition, over 75-years
- Country Music Singer/Songwriter Ashley Wineland To Drop Full-Length Album 'I'm Gonna Ride'
Currently, 45 market competitors compose the exosome industry, with 19 of them being established companies that have recently joined the race to develop aging-defying exosome technology. Some of these companies include: Galderma S.A., Johnson & Johnson, Allergen, El. En. SpA, Alma Lasers, Cynosure, Lumenis, Solta Medical, Syneron Candela, and Merz Pharma.
Up and coming regenerative biotech company Elevai shows award winning promise with stem cell exosome topical applications as the next generation of targeted anti-aging skin care. Elevai recently won the LaunchPad SBDC People's Choice Award at the 2022 Octane Aesthetics Tech Summit ("ATS") held in Newport Beach, California, for their proprietary stem cell exosome technology and products. The Elevai platform technology illuminates potential applications in regenerative medicine and in office medical skincare treatments.
Another company worth mentioning includes Jeune, a gene-based aesthetic subsidiary of Krystal biotech, that is currently operating the first-in-human Phase 1 clinical trial of an injectable gene therapy to stimulate production of collagen type III and reduce wrinkles. The injections were well tolerated and biopsies at the injection sites showed new collagen generation, an excellent first step to directly address biological changes in the skin associated with intrinsic and extrinsic aging.
More on Michimich.com
- Oak Real Estate Partners Launches $500 Million Fund for Institutional Investors
- Lafayette West, $150M Development, Breaks Ground in Historic Lafayette Park
- UVeye to Help Streamline Vehicle Service at Dealerships With Fortellis Automotive Commerce Exchange TM
- Grayhawk Capital Receives U.S. Small Business Administration Investment Company of the Year Award
- ThoroughCare Announces $3 Million Capital Raise to Advance Care Coordination for Value-Based Care
Stem cell exosomes and gene therapy technologies will no doubt become the in office standard of care for regenerative and anti-aging technology, stealing the stage much in the same way that insulin radically changed diabetic care.
Source: Braeden William Lichti
Filed Under: Business
0 Comments
Latest on Michimich.com
- Premium Brands Enter Santé Wine & Spirits Competition
- Green Science Solutions To Demo Gold Standard Cleaning Platform For Healthier Senior Living At Argentum 2022
- Kano Laboratories Introduces Kroil Penetrant with Graphite for High Temperature Environments
- Teenear Samples Brandy's "The Boy Is Mine" on her Single Release Ain't Mine - Available May 13th on all streaming platforms
- African Arts Academy Hosts Modern Ethnic Fashion Show in San Francisco communities
- Agree Realty Declares Monthly Common and Preferred Dividends
- 1040 Abroad offers an incentive to existing customers to refer a friend, while reminding expatriates of the upcoming June 15, 2022 deadline
- Teijin Automotive Technologies Breaks Ground for Huntington, Indiana, Facility Expansion
- IndyGeneUS AI Awarded Grant Funding through QuickFire Challenge
- Students From Highpoint Virtual Academy to Be Celebrated With Their First-Ever In-Person Graduation Ceremony
- Platinum Educational Group Continues to Support Health Professional Students
- Five to Flow and NTeli Form Strategic Partnership to Improve Business Performance on Technology Transformation Programs
- Asia's First Decentralized NFT-Fi Platform SOLARR Raises $2M to Bring NFT Use Cases Mainstream
- The Business of Reversing Broken Homes
- TAG MultiMedia partners with CodeBaby, Inc. to bring Conversational AI to marketplace
- NEAT Glass to be the Official Judging Glass of The CHILLED 100 Spirits Awards
- Plinqit Named a Founding Sponsor of San Diego Wave FĂștbol Club, the Newest Member of the National Women's Soccer League
- BACA Systems Hires Account Executives to Lead Business Development, Manage Customer Relationships in Six States
- The Best Way To Protect Yourself From Ransomware
- How to Find the Right Debt Collection Agency Online